Agomab Therapeutics, a clinical-stage biotechnology company focused on fibrosis, has announced its participation in two upcoming scientific conferences in May 2026. The company will present data from its pipeline, including its lead candidate AGMB-129, a small molecule inhibitor of ALK5 for the treatment of fibrotic diseases.
On May 18, 2026, Agomab will present at the International Symposium on Idiopathic Pulmonary Fibrosis (ISIPF) in Boston, Massachusetts. The presentation will highlight preclinical data on AGMB-129 in models of pulmonary fibrosis.
Additionally, on May 25, 2026, Agomab will participate in the European Congress on Fibrosis Research in Berlin, Germany. The company will showcase updated results from its ongoing Phase 2a trial of AGMB-129 in patients with idiopathic pulmonary fibrosis (IPF).
Agomab's CEO, Dr. Tim Knotnerus, stated, 'We are excited to share our progress with the scientific community and discuss the potential of AGMB-129 to address unmet needs in fibrosis.' The company's stock is traded on the Euronext Brussels exchange under the ticker AGMB.
